Drug Evaluation Committee Conveying Clinical Trial Information in an Easy-to-understand Way To Pharmaceutical Companies that Prepare Documents for Non-specialists
Data Science Subcommittee
June 2024
In recent years, as information on clinical trials has become more publicly available and patients and the public have more opportunities to directly access this information, issues related to the content of the publicly available information (e.g., difficulty or incomprehension of the content) have become apparent. As one response to this issue, we have organized points to keep in mind in order to convey clinical trial information in an easy-to-understand manner to pharmaceutical company personnel who prepare documents read by patients and citizens who are not medical experts. We hope that this report will help realize better health communication between patients/citizens and pharmaceutical companies in the future.
This report is reprinted from the "Guide to Communicating Medical Research in an Easy-to-Understand Way" prepared by the "Project for Communicating Medical Information in an Easy-to-Understand Way". We would like to express our deep appreciation to the members of the "Project for Communicating Medical Information in an Easy-to-Understand Way" for their permission to reproduce this document.
Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee
Data Science Subcommittee 2023 Task Force 2-3